InnovaCare Health: Leading Provider of Healthcare Management

InnovaCare Health is on a mission to redefine healthcare management. Today’s healthcare environment is complex and overwhelming. In light of recent events, the healthcare environment promises to become even more complicated. Thankfully, companies like InnovaCare Health are trying to remove the challenges of healthcare management.

InnovaCare focuses on creating and maintaining strong patient-provider relationships. Much of InnovaCare’s resources go toward building better models of managed care. With the help of their subsidiaries, these models are more coordinated, cost-effective, and driven by quality. InnovaCare’s been recognized numerous times for their innovative models.

At InnovaCare, they always put patients first. Everything they do centers on providing the absolute best quality medical care they can. To provide the best medical care, there have to be strong patient-provider relationships. If patients don’t trust their providers, they’re less likely to inform their provider of crucial medical information.

InnovaCare also tries its best to have the best medical practices and networks. Every member of the InnovaCare team is at the apex of their field with years of experience. Everything works best when stakeholders are held accountable. That’s why InnovaCare’s leadership takes their roles in the company seriously. The company always maintains a level of transparency with the public. Learn more about Innovacare at Businesswire.

Part of InnovaCare leadership is Dr. Richard Shinto, President and CEO of InnovaCare, Inc. Dr. Shinto’s worked in clinical and operational healthcare for over 20 years. He’s managed numerous companies, all working in the managed care industry. He’s also the CEO of InnovaCare’s Health Plans in Puerto Rico.

Dr. Shinto earned his medical degree from the State University of New York. He also holds two other degrees: a B.S. from the University of California and an M.B.A. from the University of Redlands. Since then, he’s received medical tenure in Southern California.

Another bright light at InnovaCare Health is Penelope Kokkinides, Chief Administrative Officer. In 2015, Kokkinides rejoined the company after exploring other options. Kokkinides spent over 20 years working with specialized government programs and the managed care industry. She has extensive experience developing clinical programs and managing health care operations. Contact details available at

Kokkinides also holds several degrees. She has a Bachelor’s from Binghamton University. She also studied social work at New York University, where she earned a Master’s degree. She even studied at Columbia University School of Public Health.

Mikhail Blagosklonny Advocates the Use of Rapamycin in Cancer and Aging Treatment

Mikhail Blagosklonny is the appropriate scientist to be consulted in a field that requires one to study and understand cancer and aging. The former professor of Oncology at New York’s Roswell Park Cancer Institute has managed to train several oncologists. Mikhail earned is Doctor of Medicine Degree in Internal Medicine at the First Pavlov State Medical University of St. Petersburg. He later received his Ph.D. in Experimental Medicine and Cardiology from the same University. Mikhail was an associate professor of Medicine at New York Medical College for seven years before he was appointed as Oncology, a professor at Roswell Park Cancer Institute. He has done several types of research on cancer and its therapies that do not damage healthy cells. Mikhail has also done research on aging and anti-aging drugs. Read more on

Use of Rapamycin in the treatment of cancer and aging

In a paper that was published by Impact Journal, Mikhail says that aging is not a disease and trying to cure it is misguided and not scientific. In this paper, aging is described as a continuous growth that is enhanced by signaling pathways such as TOR. The TOR centric model has got three sources namely; genetic longevity, cellular senescence, and diseases. It was also predicted that Rapamycin could be used to treat aging and diseases related to it. The prediction was made in 2008 and was taken for granted by opponents as it was not viable to them. Eight years later, it is becoming a turning point in scientific research.

In 2006, rapamycin was approved for use clinically. It was immediately administered to treat diseases like autoimmunity, metabolic disorders, cardiovascular disorders, and cancer. The drug can be administered to patients for an extended period without adverse side effects. It rejuvenates the patients’ immunity, unlike other drugs that suppress the immunity. The drug can be administered orally and on a daily basis. It is safe and not toxic to the body cells.

Know more:

Prof. Mikhail Blagosklonny is currently working as the editor-in-chief of Oncotarget and Cell Cycle. He serves on the editorial board that deals with cell death and differentiation. His research covers several areas of cellular and molecular biology and clinical trials. In his research, Mikhail focuses on transduction, cell apoptosis, tumor suppression, and cell cycle. He also deals with drug resistance for cells that are healthy, mitosis and anticancer therapeutics. He has more than 300 articles that give insight on cancer cure and anti-aging drugs. Mikhail is among one of the most know rapamycin advocates. His day to day research work is driven by his desire to see a disease free world. The professor is a scientific researcher who has put a lot of dedication into his work making one of the best oncologists globally.